JP2016539122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539122A5 JP2016539122A5 JP2016533187A JP2016533187A JP2016539122A5 JP 2016539122 A5 JP2016539122 A5 JP 2016539122A5 JP 2016533187 A JP2016533187 A JP 2016533187A JP 2016533187 A JP2016533187 A JP 2016533187A JP 2016539122 A5 JP2016539122 A5 JP 2016539122A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- administered
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201314086696A | 2013-11-21 | 2013-11-21 | |
| CA2834000A CA2834000A1 (en) | 2013-11-21 | 2013-11-21 | Method for treating a gd2 positive cancer |
| EP13193953.0A EP2875827A1 (en) | 2013-11-21 | 2013-11-21 | Preparations and methods for treating a GD2 positive cancer |
| CA2834000 | 2013-11-21 | ||
| EP13193953.0 | 2013-11-21 | ||
| US14/086,696 | 2013-11-21 | ||
| US14/182,776 US10294305B2 (en) | 2012-06-18 | 2014-02-18 | Method for treating a GD2 positive cancer |
| US14/182,776 | 2014-02-18 | ||
| PCT/EP2014/075315 WO2015075194A1 (en) | 2013-11-21 | 2014-11-21 | Preparations and methods for treating a gd2 positive cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142173A Division JP7139293B2 (ja) | 2013-11-21 | 2019-08-01 | Ｇｄ２陽性がんを処置するための製剤および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539122A JP2016539122A (ja) | 2016-12-15 |
| JP2016539122A5 true JP2016539122A5 (enExample) | 2017-08-31 |
| JP6693873B2 JP6693873B2 (ja) | 2020-05-13 |
Family
ID=53179006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533187A Active JP6693873B2 (ja) | 2013-11-21 | 2014-11-21 | Ｇｄ２陽性がんを処置するための製剤および方法 |
| JP2019142173A Active JP7139293B2 (ja) | 2013-11-21 | 2019-08-01 | Ｇｄ２陽性がんを処置するための製剤および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142173A Active JP7139293B2 (ja) | 2013-11-21 | 2019-08-01 | Ｇｄ２陽性がんを処置するための製剤および方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995147B2 (enExample) |
| EP (2) | EP3071220B1 (enExample) |
| JP (2) | JP6693873B2 (enExample) |
| AU (2) | AU2014351796B2 (enExample) |
| CA (1) | CA2930285A1 (enExample) |
| CY (1) | CY1122508T1 (enExample) |
| DK (1) | DK3071220T3 (enExample) |
| EA (1) | EA201691055A1 (enExample) |
| ES (1) | ES2768649T3 (enExample) |
| HR (1) | HRP20200128T1 (enExample) |
| HU (1) | HUE047920T2 (enExample) |
| LT (1) | LT3071220T (enExample) |
| NZ (1) | NZ720273A (enExample) |
| PL (1) | PL3071220T3 (enExample) |
| PT (1) | PT3071220T (enExample) |
| RS (1) | RS59817B1 (enExample) |
| SI (1) | SI3071220T1 (enExample) |
| SM (1) | SMT202000027T1 (enExample) |
| WO (1) | WO2015075194A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| JP6693873B2 (ja) * | 2013-11-21 | 2020-05-13 | アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ | Ｇｄ２陽性がんを処置するための製剤および方法 |
| RU2663104C1 (ru) * | 2017-07-13 | 2018-08-01 | Общество с ограниченной ответственностью "Реал Таргет" | Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей |
| KR20200059249A (ko) * | 2017-09-21 | 2020-05-28 | 유엠씨 우트레크트 홀딩 비.브이. | 신경아세포종의 치료를 위한 항-gd2 항체 |
| CN115835884A (zh) * | 2020-07-06 | 2023-03-21 | 尤萨制药(英国)有限公司 | 治疗gd2阳性癌症的方法 |
| WO2026053122A1 (en) * | 2024-09-04 | 2026-03-12 | Dana-Farber Cancer Institute, Inc. | Methods of treating retinoid responsive cancers |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| JP4494977B2 (ja) | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 |
| ATE443724T1 (de) | 2004-01-22 | 2009-10-15 | Merck Patent Gmbh | Antikrebs-antikörper mit reduzierter komplementfixierung |
| WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| CN102164962B (zh) | 2008-06-30 | 2014-05-28 | 诺福泰克公司 | 抗gd2抗体和方法及其相关应用 |
| KR101834026B1 (ko) | 2010-06-19 | 2018-03-02 | 메모리얼 슬로안-케터링 캔서 센터 | 항-ｇｄ2 항체 |
| JP5623999B2 (ja) | 2010-08-31 | 2014-11-12 | パナソニック株式会社 | 電子装置 |
| HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| JP6693873B2 (ja) | 2013-11-21 | 2020-05-13 | アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ | Ｇｄ２陽性がんを処置するための製剤および方法 |
-
2014
- 2014-11-21 JP JP2016533187A patent/JP6693873B2/ja active Active
- 2014-11-21 HR HRP20200128TT patent/HRP20200128T1/hr unknown
- 2014-11-21 HU HUE14802642A patent/HUE047920T2/hu unknown
- 2014-11-21 DK DK14802642.0T patent/DK3071220T3/da active
- 2014-11-21 WO PCT/EP2014/075315 patent/WO2015075194A1/en not_active Ceased
- 2014-11-21 SI SI201431460T patent/SI3071220T1/sl unknown
- 2014-11-21 LT LTEP14802642.0T patent/LT3071220T/lt unknown
- 2014-11-21 RS RS20200053A patent/RS59817B1/sr unknown
- 2014-11-21 PT PT148026420T patent/PT3071220T/pt unknown
- 2014-11-21 PL PL14802642T patent/PL3071220T3/pl unknown
- 2014-11-21 EP EP14802642.0A patent/EP3071220B1/en active Active
- 2014-11-21 SM SM20200027T patent/SMT202000027T1/it unknown
- 2014-11-21 EA EA201691055A patent/EA201691055A1/ru unknown
- 2014-11-21 ES ES14802642T patent/ES2768649T3/es active Active
- 2014-11-21 NZ NZ720273A patent/NZ720273A/en unknown
- 2014-11-21 AU AU2014351796A patent/AU2014351796B2/en active Active
- 2014-11-21 EP EP19203951.9A patent/EP3620173A1/en not_active Withdrawn
- 2014-11-21 CA CA2930285A patent/CA2930285A1/en active Pending
-
2019
- 2019-08-01 JP JP2019142173A patent/JP7139293B2/ja active Active
-
2020
- 2020-01-21 CY CY20201100048T patent/CY1122508T1/el unknown
- 2020-05-22 AU AU2020203346A patent/AU2020203346A1/en not_active Abandoned
- 2020-07-06 US US16/920,880 patent/US10995147B2/en active Active
-
2021
- 2021-03-03 US US17/190,792 patent/US11492412B2/en active Active
-
2023
- 2023-03-06 US US18/178,778 patent/US20240158530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539122A5 (enExample) | ||
| JP2015521607A5 (enExample) | ||
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| Perez et al. | Update on the use of immunoglobulin in human disease: a review of evidence | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| EA033400B1 (ru) | Антитело против cd3 и его применение | |
| PH12015501531B1 (en) | Crenolanib for treating flt3 mutated proliferative disorders | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2016530280A5 (enExample) | ||
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2012102122A5 (enExample) | ||
| JP2017501848A5 (enExample) | ||
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| ZA202201946B (en) | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| BR112017004590A2 (pt) | métodos para o tratamento de doença autoimune com o uso de um anticorpo de domínio direcionado contra cd40l | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| JP2018522881A5 (enExample) | ||
| Slade et al. | Changing practice: no need to stop ACE inhibition for venom immunotherapy | |
| FI3298042T3 (fi) | B-solujen vähentyminen diagnostisena merkkinä | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| JP2017530142A5 (enExample) | ||
| MX2021003668A (es) | Composición de ketamina para su uso en un método de tratamiento de la depresión por administración pulmonar. |